Therapeutic Approach to Alzheimer’s Disease: Current Treatments and New Perspectives
Open accessThe DOI matches its Crossref record; 155 of the 158 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia. The pathophysiology of this disease is characterized by the accumulation of amyloid-β, leading to the formation of senile plaques, and by the intracellular presence of neurofibrillary tangles based on hyperphosphorylated tau protein. In the therapeutic approach to AD, we can identify three important fronts: the approved drugs currently available for the treatment of the disease, which include aducanumab, donepezil, galantamine, rivastigmine, memantine, and a combination of memantine and donepezil; therapies under investigation that work mainly on Aβ pathology and tau pathology, and which include γ-secretase inhibitors, β-secretase inhibitors, α-secretase modulators, aggregation inhibitors, metal interfering drugs, drugs that enhance Aβ clearance, inhibitors of tau protein hyperphosphorylation, tau protein aggregation inhibitors, and drugs that promote the clearance of tau, and finally, other alternative therapies designed to improve lifestyle, thus contributing to the prevention of the disease. Therefore, the aim of this review was to analyze and describe current treatments and possible future alternatives in the therapeutic approach to AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It modulates glutamate transmission and dopamine receptors, exhibiting certain efficacy in improving patients’ cognitive function, daily living abilities, and behavior.409,410”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [410]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Donepezil, galantamine, and rivastigmine are the cholinesterase inhibitors that are most frequently prescribed [102,103,104,105,106].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [103]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“This study showed a dose-time-dependent reduction in Aβ plaques and an improvement in clinical manifestations of AD, as assessed by the Clinical Dementia RatingSum of Boxes (CDR-SB) and Mini Mental State Examination (MMSE) scores for the highest dose [20].”
MethodCraft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · cited 2×
“However, despite the good results obtained in in vivo studies, no improvement in cognitive status, and no reduction of tau in the CSF of patients under treatment was observed [104,105].”
BackgroundTrial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705971 · Cited by 1,049 · cited 1×
“A phase 2 study involving individuals with prodromal AD, and a phase 3 clinical trial studying the efficacy of this treatment at disease onset are currently underway [100,101].”
BackgroundBeneficial effects of physical exercise on neuroplasticity and cognition
Hötting, K., & Röder, B. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.04.005 · Cited by 991
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966 · cited 3×
“In one phase 3 clinical trial, participants with mild and moderate AD showed good tolerability, but no decrease in cognitive and functional impairment [75].”
BackgroundInfluential
Research works printed but not linked: 1
- Buchanan, T., De Bruyn, S., Fadini, T., Watanabe, S., Germani, M., and Mesa, A.B.I.R. (2019, January 22–26). A Randomised, Placebo-Controlled, First-in-Human Study with a Central Tau Epitope Antibody–UCB0107. Proceedings of the International Congress of Parkinson’s Disease and Movement Disorders, Nice, France.
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
Singh, B., Day, C. M., Abdella, S., & Garg, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.047 · Cited by 228
Rahimi Darehbagh, R., Seyedoshohadaei, S. A., Ramezani, R., & Rezaei, N. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01987-1 · Cited by 167
Neuroinflammation in Neurodegenerative Disorders: Current Knowledge and Therapeutic Implications
Giri, P. M., Banerjee, A., Ghosal, A., & Layek, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073995 · Cited by 142
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 120
Neuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders
García‐Domínguez, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060417 · Cited by 103
Aducanumab—Hope or Disappointment for Alzheimer’s Disease
Wojtunik-Kulesza, K., Rudkowska, M., & Orzeł-Sajdłowska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054367 · Cited by 73
Selenization of Small Molecule Drugs: A New Player on the Board
Morán‐Serradilla, C., Plano, D., Sanmartín, C., & Sharma, A. K. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02426 · Cited by 74
Ramakrishna, K., Karuturi, P., Siakabinga, Q., Gajendra, T. A., Krishnamurthy, S., Shreya, S., Kumari, S., Kumar, G. S., Sobhia, M. E., & Nand, S. (2024) · Diseases · doi:10.3390/diseases12080184 · Cited by 80
The complement system in neurodegenerative diseases
Nimmo, J., Byrne, R. A. J., Daskoulidou, N., Watkins, L. M., Carpanini, S. M., Zelek, W. M., & Morgan, B. P. (2024) · Clinical Science · doi:10.1042/cs20230513 · Cited by 61
Cadmium neurotoxicity: Insights into behavioral effect and neurodegenerative diseases
Rezaei, K., Mastali, G., Abbasgholinejad, E., Bafrani, M. A., Shahmohammadi, A., Sadri, Z., & Zahed, M. A. (2024) · Chemosphere · doi:10.1016/j.chemosphere.2024.143180 · Cited by 58
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024) · Molecules · doi:10.3390/molecules29215131 · Cited by 56
Tear Biomarkers and Alzheimer’s Disease
Kaštelan, S., Braš, M., Pjevač, N., Bakija, I., Tomić, Z., Pjevač, N., & Antunica, A. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713429 · Cited by 57
Sharma, A., Rudrawar, S., Bharate, S. B., & Jadhav, H. R. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00630e · Cited by 70
Liu, W., Li, Y., Zhao, T., Gong, M., Wang, X., Zhang, Y., Xu, L., Li, W., Li, Y., & Jia, J. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102534 · Cited by 46
Monoclonal Antibody Therapy in Alzheimer’s Disease
Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 48
Dehghani, S., Ocakcı, O., Hatipoglu, P. T., Özalp, V. C., & Tevlek, A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04825-5 · Cited by 55
Dendrimers in Alzheimer’s Disease: Recent Approaches in Multi-Targeting Strategies
Arbez‐Gindre, C., Steele, B. R., & Micha‐Screttas, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030898 · Cited by 49
Shi, D., Hao, Z., Qi, W., Jiang, F., Liu, K., & Shi, X. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1269952 · Cited by 46
Zang, W.-B., Wei, H., Zhang, W., Ma, W., Li, J., & Yao, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116070 · Cited by 50
Therapeutic potential of the medicinal mushroom Ganoderma lucidum against Alzheimer's disease
Chen, X.-J., Deng, Z., Zhang, L., Pan, Y., Fu, J., Zou, L., Bai, Z., Xiao, X., & Sheng, F. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116222 · Cited by 51
Newer Therapeutic Approaches in Treating Alzheimer’s Disease: A Comprehensive Review
Sree, R. R., Kalyan, M., Anand, N., Mani, S., Gorantla, V. R., Sakharkar, M. K., Song, B., & Chidambaram, S. B. (2025) · ACS Omega · doi:10.1021/acsomega.4c05527 · Cited by 56
Pyka, P., Haberek, W., Więcek, M., Szymańska, E., Ali, W., Cios, A., Jastrzębska‐Więsek, M., Satała, G., Podlewska, S., Giacomo, S. D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02148 · Cited by 43
Inosine in Neurodegenerative Diseases: From the Bench to the Bedside
Basile, M. S., Bramanti, P., & Mazzon, E. (2022) · Molecules · doi:10.3390/molecules27144644 · Cited by 44
Drug Development for Alzheimer’s and Parkinson’s Disease: Where Do We Go Now?
Sequeira, L., Benfeito, S., Fernandes, C., Gaspar, A., Lima, I., Peixoto, J., Alves, C., Machado, C. S., Borges, F., & Chavarria, D. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060708 · Cited by 42
Gut-brain axis and Alzheimer's disease: Therapeutic interventions and strategies
Singh, H., Chopra, C., Singh, H., Malgotra, V., Wani, A. K., Dhanjal, D. S., Sharma, I., Nepovimová, E., Alomar, S. Y., Singh, R., et al. (2023) · Journal of Functional Foods · doi:10.1016/j.jff.2023.105915 · Cited by 43
Sonawane, D., & Pokharkar, V. (2024) · AAPS PharmSciTech · doi:10.1208/s12249-024-02736-7 · Cited by 41
Ailioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 44
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
Dave, B. P., Shah, Y. B., Maheshwari, K. G., Mansuri, M. K. A., Prajapati, B., Postwala, H. I., & Chorawala, M. R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01408-7 · Cited by 37
Shaaban, A. E., Ali, A. R., Ayyad, S.-E. N., & Badria, F. A. A.-R. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.108075 · Cited by 36
The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for Diagnosis and Therapy
Wang, T., & Jia, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512025 · Cited by 34
Microglia as a cellular target of diclofenac therapy in Alzheimer’s disease
Stopschinski, B. E., Weideman, R. A., McMahan, D., Jacob, D. A., Little, B. B., Chiang, H.-S., Saez Calveras, N., & Stuve, O. (2023) · Therapeutic Advances in Neurological Disorders · doi:10.1177/17562864231156674 · Cited by 26
Protective Effect of Galantamine against Doxorubicin-Induced Neurotoxicity
Alsikhan, R. S., Aldubayan, M. A., Almami, I. S., & Alhowail, A. H. (2023) · Brain Sciences · doi:10.3390/brainsci13060971 · Cited by 27
Zelek, W. M., Bevan, R. J., & Morgan, B. P. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.03.017 · Cited by 26
Natural products targeting amyloid-β oligomer neurotoxicity in Alzheimer's disease
Gonçalves, P. B., Sodero, A. C. R., & Cordeiro, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116684 · Cited by 27
Sonwani, A., Pathak, A., & Jain, K. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105855 · Cited by 27
Yun, D., Wang, Y., Zhang, Y., Jia, M., Xie, T., Zhao, Y., Yang, C., Chen, W., Guo, R., Liu, X., et al. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c04292 · Cited by 25
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases
Xing, C., Chen, H., Bi, W., Lei, T., Hang, Z., & Du, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413446 · Cited by 26
Patil, N., Dhariwal, R., Mohammed, A., Wei, L. S., & Jain, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28852 · Cited by 27
Zelek, W. M., Bevan, R. J., Nimmo, J., Dewilde, M., Strooper, B. D., & Morgan, B. P. (2024) · Brain · doi:10.1093/brain/awae278 · Cited by 26
Mishra, K. A., & Sethi, K. K. (2024) · Archiv der Pharmazie · doi:10.1002/ardp.202400748 · Cited by 23
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 23
Cai, Y., Li, Y., Wang, Y., Xu, Y., Chen, T., Xue, R., Liu, Y., Chen, W., Yang, X., Liu, Z., et al. (2024) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2024.117078 · Cited by 23
Zhou, W., Lei, B., Yang, C., Silva, M., Xing, X., Yu, H., Lu, J., & Zheng, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065259 · Cited by 23
Symptoms and conventional treatments of Alzheimer's disease
Chorawala, M. R., Shah, A. C., Pandya, A. J., Kothari, N. R., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00009-1 · Cited by 20
Non-Invasive Retinal Biomarkers for Early Diagnosis of Alzheimer’s Disease
Kaštelan, S., Antunica, A. G., Puzović, V., Pavičić, A. D., Čanović, S., Kovačević, P., Vučemilović, P. A. F., & Konjevoda, S. (2025) · Biomedicines · doi:10.3390/biomedicines13020283 · Cited by 27
Gugliandolo, A., Blando, S., Salamone, S., Caprioglio, D., Pollastro, F., Mazzon, E., & Chiricosta, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076598 · Cited by 15
Li, J., Wu, X., Tan, X., Wang, S., Qu, R., Wu, X., Chen, Z., Wang, Z., & Chen, G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1257973 · Cited by 20
Ginkgo biloba and Its Chemical Components in the Management of Alzheimer’s Disease
Peng, Y., Chen, Q., Xue, Y.-H., Jin, H., Liu, S., Du, M., & Yao, S. (2024) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x24500277 · Cited by 23
Qi, X., Nizamutdinov, D., Yi, S. S., Wu, E., & Huang, J. H. (2024) · Biomedicines · doi:10.3390/biomedicines12112636 · Cited by 19
A Pilot Study of Near-Infrared Light Treatment for Alzheimer’s Disease
Chen, L., Xue, J., Zhao, Q., Liang, X., Zheng, L., Fan, Z., Souare, I. S. J., Suo, Y., Wei, X., Ding, D., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220866 · Cited by 18
Mitophagy in Neurodegenerative Diseases: Mechanisms of Action and the Advances of Drug Discovery
Yang, P., Wen, S., Wang, X., Hu, X., Zhao, M., Wang, A., Wu, Y., Ouyang, L., & Wang, G. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01779 · Cited by 18
Kola, A., Lamponi, S., Currò, F., & Valensin, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032500 · Cited by 21
Dimkovski, A., Dobričić, V., Simić, M. R., Pavlova, M. J., Mihajloska, E., Sterjev, Z., & Panovska, A. P. (2025) · Molecules · doi:10.3390/molecules30102121 · Cited by 16
Anti-inflammatory effect of curcumin on neurological disorders: a narrative review
Zhou, B., & Hu, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1658115 · Cited by 24
Karthivashan, G., & Kar, S. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01957-5 · Cited by 17
Cell primitive-based biomimetic nanomaterials for Alzheimer's disease targeting and therapy
Yin, T., Liu, Y., He, B., Gong, B., Chu, J., Gao, C., Liang, W., Hao, M., Sun, W., Zhuang, J., et al. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100789 · Cited by 17
Peng, L., Zhang, Z., Li, Q., Song, Z., Yan, C., & Ling, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39217 · Cited by 21
Zhou, Q., Wang, W., & Deng, C. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-04838-0 · Cited by 21
An inclusive study of recent advancements in Alzheimer's disease: A comprehensive review
Singh, S., Mahajan, M., Kumar, D., Singh, K., Chowdhary, M., & Amit (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102369 · Cited by 17
Zou, J., Zhang, X. Q., Guo, Q. W., Xu, X. H., Liu, W. W., Zhang, F. L., & Shi, D. H. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.138203 · Cited by 14
Glycyrrhizin and its derivatives: an emerging secondary metabolite arsenal of Glycyrrhiza glabra
Rasool, A., & Dar, T. A. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03376-7 · Cited by 16
Mohamed-Mohamed, H., García‐Morales, V., Sanchez-Lara, E., González‐Acedo, A., Pardo-Moreno, T., Tovar-Gálvez, M. I., Melguizo‐Rodríguez, L., & Ramos‐Rodríguez, J. J. (2023) · Neurology International · doi:10.3390/neurolint15040079 · Cited by 16
Self-citationMahadik, N., Barron, G. A., Lin, P. K. T., & Thompson, C. J. (2024) · RSC Pharmaceutics · doi:10.1039/d3pm00075c · Cited by 17
Exosomes and non-coding RNAs: bridging the gap in Alzheimer’s pathogenesis and therapeutics
Chunhui, G., You, Y., Chen, J., Luo, N., & Li, F. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-024-01520-7 · Cited by 13
Roadmap on nanomedicine for the central nervous system
Ciofani, G., Campisi, M., Mattu, C., Kamm, R. D., Chiono, V., Raynold, A. A. M., Freitas, J. S., Riva, E. R., Micera, S., Pucci, C., et al. (2022) · Journal of Physics Materials · doi:10.1088/2515-7639/acab88 · Cited by 12
Wang, Y., Liu, Q., Lv, Q., Yang, K., Wu, X., Zheng, Y., Xiao, P., Jiang, B., & He, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114394 · Cited by 13
Unraveling the mystery of citrate transporters in Alzheimer’s disease: An updated review
Mukherjee, A. G., Mishra, S., Gopalakrishnan, A. V., Kannampuzha, S., Murali, R., Wanjari, U. R., Stany, B. K., Vellingiri, B., Madhyastha, H., Deepankumar, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102726 · Cited by 12
Renesteen, E., Boyajian, J. L., Islam, P., Kassab, A., Abosalha, A. K., Makhlouf, S., Santos, M., Chen, H., Shum-Tim, C., & Prakash, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115351 · Cited by 16
Plekratoke, K., Boonyarat, C., Monthakantirat, O., Nualkaew, N., Wangboonskul, J., Awale, S., Chulikhit, Y., Daodee, S., Khamphukdee, C., Chaiwiwatrakul, S., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45050259 · Cited by 15
Nanostructured Lipid Carriers of Donepezil Hydrochloride for the Treatment of Alzheimer’s Disease
Tekade, A. R., Susar, R., Kulkarni, G., Surwade, S., & Gaikwad, A. (2024) · Current Alzheimer Research · doi:10.2174/0115672050288659240229080535 · Cited by 11
Foroughi, S., Shahanipour, K., Monajemi, R., & Ahadi, A. M. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148966 · Cited by 11
Liu, X., She, W., Sung, H. H. Y., Williams, I. D., & Qian, P. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123170 · Cited by 11
Aurelian, S. M., Ciobanu, A. M., Carare, R. O., Stoica, S. I., Anghelescu, A., Ciobanu, V., Onose, G., Munteanu, C., Popescu, C., Andone, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216533 · Cited by 13
Thu, D. K., Hong, S., Dao, V. T., Nguyen, T.-D., Nguyen, K. V., Nguyen, H. T., Ullah, S., Tran, T. H., & Kim, S. Y. (2022) · Phytotherapy Research · doi:10.1002/ptr.7602 · Cited by 10
Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease
Elghanam, Y., Purja, S., & Kim, E. Y. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240008 · Cited by 11
Khare, N., Barot, M., Singh, S., & Jain, T. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01389-4 · Cited by 9
Chauhan, P., Wadhwa, K., & Singh, G. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156109 · Cited by 12
Akbar, F., Alkhrijah, Y. M., Usman, S. M., Khalid, S., Ihsan, I., & Alawad, M. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-28070-x · Cited by 12
Donepezil-based combination therapy for Alzheimer’s disease and related neuropathies
Ekundayo, B. E., Obafemi, T. O., Adewale, O. B., & Oyinloye, B. E. (2023) · Comparative Clinical Pathology · doi:10.1007/s00580-023-03487-w · Cited by 8
Yoon, E., Ahn, J. W., Kim, H.-S., Choi, Y., Jeong, J., Joo, S. S., & Park, D. (2023) · Nutrients · doi:10.3390/nu15153389 · Cited by 11
Xue, H., Li, Y., Xiao, Y.-S., Fan, W.-H., & He, H. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1383278 · Cited by 14
Célestine, M., Jacquier‐Sarlin, M. R., Borel, E., Petit, F., Lanté, F., Bousset, L., Hérard, A., Buisson, A., & Dhénain, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02611-8 · Cited by 7
Minuti, A., Mazzon, E., Iori, R., Chiricosta, L., & Artimagnella, O. (2024) · Nutrients · doi:10.3390/nu16234202 · Cited by 9
Review on pathogenesis and treatment of Alzheimer's disease
Cai, J., Liu, Y., & Fan, H. (2024) · Developmental Dynamics · doi:10.1002/dvdy.762 · Cited by 11
Guo, R., Li, D., Li, F., Ji, L., Liu, H.-H., Qiao, H., Lv, Z., Tang, Y., & Wang, D. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251313819 · Cited by 8
Svobodová, B., Moravcová, Z., Misiachna, A., Nováková, G., Marek, A., Finger, V., Odvarkova, J., Pejchal, J., Karasová, J. Ž., Netolický, J., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117678 · Cited by 10
Chiricosta, L., Minuti, A., Gugliandolo, A., Salamone, S., Pollastro, F., Mazzon, E., & Artimagnella, O. (2024) · Cells · doi:10.3390/cells13121012 · Cited by 7
Non-Drug and Non-Invasive Therapeutic Options in Alzheimer’s Disease
Şovrea, A. S., Boşca, A. B., Dronca, E., Constantin, A.-M., Crintea, A., Suflețel, R. T., Lupean, R.-A., Ștefan, P.-A., Onofrei, M. M., Tschall, C., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13010084 · Cited by 10
Glial Cells in Alzheimer’s Disease: Pathogenic Mechanisms and Therapeutic Frontiers
Sil, M., Mukherjee, N., Chatterjee, I., Ghosh, A., & Goswami, A. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02379-8 · Cited by 9
The therapeutic efficacy of nanoparticles in the treatment of alzheimer’s disease
Ntondini, T. L., Naki, T., & Alven, S. (2025) · Acta Neurologica Belgica · doi:10.1007/s13760-025-02905-w · Cited by 8
Ciccone, L., Camodeca, C., Tonali, N., Barlettani, L., Rossello, A., Fruchart‐Gaillard, C., Kaffy, J., Petrarolo, G., Motta, C. L., Nencetti, S., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102369 · Cited by 7
Czarnota-Łydka, K., Kucwaj‐Brysz, K., Pyka, P., Haberek, W., Podlewska, S., & Handzlik, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158768 · Cited by 7
Multitargeting Histamine H3 Receptor Ligands among Acetyl- and Propionyl-Phenoxyalkyl Derivatives
Łażewska, D., Kaleta, M., Zaręba, P., Godyń, J., Dubiel, M., Honkisz-Orzechowska, E., Doroż-Płonka, A., Więckowska, A., Stark, H., & Kieć‐Kononowicz, K. (2023) · Molecules · doi:10.3390/molecules28052349 · Cited by 7
Management of Alzheimer's Disease With Nanotechnological Interventions and Novel Therapeutics
Shahrukh, M., Ahmad, S., Zaafar, M., Hasan, N., & Ahmad, F. J. (2025) · Drug Development Research · doi:10.1002/ddr.70120 · Cited by 9
Phase-synchronized 40 Hz tACS and iTBS effects on gamma oscillations
Glinski, B., Salehinejad, M. A., Takahashi, K., Jamil, A., Yavari, F., Kuo, M., & Nitsche, M. A. (2025) · Imaging Neuroscience · doi:10.1162/imag.a.140 · Cited by 9
Molecular mechanisms underlying obesity-induced memory dysfunction: a comprehensive narrative review
Golkar, A., Razazpour, F., Dalfardi, M., & Baghcheghi, Y. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115119 · Cited by 8
Metadata
- Authors
- Pardo-Moreno, T., González-Acedo, A., Rivas-Domínguez, A., García-Morales, V., García-Cozar, F. J., Ramos-Rodríguez, J. J., & Melguizo-Rodríguez, L.
- Affiliations
- Instituto Nacional de Gestión Sanitaria (INGESA), Primary Health Care, 51003 Ceuta, Spain
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences (Melilla), University of Granada, 52005 Granada, Spain
- Universidad de Sevilla (ES)
- Department of Biomedicine, Biotechnology and Public Health, Physiology Area, Faculty of Medicine, University of Cádiz, Pl. Falla, 9, 11003 Cádiz, Spain
- Department of Biomedicine, Biotechnology and Public Health, Immunology Area, University of Cádiz Pl. Falla, 9, 11003 Cádiz, Spain
- Department of Physiology, Faculty of Health Sciences (Ceuta), University of Granada, 51001 Ceuta, Spain
- Biomedical Group (BIO277), Department of Nursing, Faculty of Health Sciences, University of Granada, 18016 Granada, Spain
- ORCID
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-05-24
- Volume
- 14
- Issue
- 6
- Pages
- 1117
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9228613
- OpenAlex
- W4281488754
- Cited by
- 239
- References
- 158
- Citations by year
- 2026: 52 · 2025: 62 · 2024: 66 · 2023: 48 · 2022: 11
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repository of the University of Granada (University of Granada) (submittedVersion, cc-by)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Deposito de Investigacion Universidad de Sevilla (University of Seville) (submittedVersion, cc-by)
- RODIN (Universidad de Cádiz) (submittedVersion, cc-by)
- Funders
- Junta de Andalucía, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
- the Ministry of Science and Innovation, Spain (P20-01293, PECART-0096-2020, PID2020-117544RB-100)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, amyloid-beta, tau hyperphosphorylation, amyloid plaques, neurofibrillary tangles, aducanumab, donepezil, galantamine, rivastigmine, memantine, gamma-secretase inhibitors, beta-secretase inhibitors, aggregation inhibitors, amyloid-beta clearance, tau aggregation inhibitors, dementia treatment, lifestyle intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.